Welcome to our dedicated page for Zymeworks SEC filings (Ticker: ZYME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zymeworks Inc. (Nasdaq: ZYME) SEC filings page on Stock Titan brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and proxy materials. These documents provide detailed information on financial results, material events, governance matters, and strategic initiatives for this global biotechnology and clinical-stage biopharmaceutical company.
Through its 8-K filings, Zymeworks reports items such as quarterly financial results, material clinical and regulatory milestones, leadership and board changes, share repurchase authorizations, and strategic initiatives related to its asset and royalty aggregation strategy. For example, recent 8-Ks describe positive topline Phase 3 HERIZON-GEA-01 results for Ziihera ® (zanidatamab-hrii), the launch of a share repurchase program, and updates on licensed products and healthcare assets. Other 8-Ks address decisions on specific pipeline programs, such as the voluntary discontinuation of clinical development for ZW171, and amendments to financing instruments like pre-funded warrants.
The company’s definitive proxy statement on Form DEF 14A offers additional insight into Zymeworks’ governance structure, board composition, committee responsibilities, executive compensation practices, and matters submitted to stockholders for approval. Together, these filings help investors understand how Zymeworks oversees its integrated model of internal R&D and royalty-driven asset management.
On Stock Titan, these SEC filings are updated as they become available from EDGAR and are paired with AI-powered summaries that highlight key points, such as revenue drivers, material clinical events, capital structure changes, and governance decisions. Users can quickly scan current and historical filings to track developments affecting Zymeworks’ licensed assets, pipeline programs, cash resources, and shareholder-related actions, without needing to read every page of the underlying documents.
Zymeworks Inc. insider holdings: SVP & Chief Medical Officer Mekan Sabeen filed an initial ownership report showing no directly owned common shares. Instead, the filing lists equity awards in the form of options and stock units.
Sabeen holds stock options for 192,000 common shares at an exercise price of $11.75 per share, expiring on April 20, 2035, from a grant on April 21, 2025, and options for 29,000 shares at $23.16 per share, expiring on January 11, 2036, from a grant on January 12, 2026. The filing also reports 19,000 restricted stock units that vest in four equal annual installments starting on the first anniversary of the January 12, 2026 grant.
In addition, Sabeen has performance stock units tied to total shareholder return goals, with a maximum of 32,000 shares potentially deliverable over a three-year performance period ending January 12, 2029. These PSUs can pay out at 50% to 200% of a 16,000-share target based on TSR performance and continued service.
Zymeworks Inc. executive Mark Hollywood, EVP & Chief Operating Officer, reported equity compensation activity on January 12, 2026. One third of previously granted restricted stock units vested, converting into 17,666 shares of common stock at no cost. To cover related tax withholding and fees under a mandatory “sell to cover” provision, 6,120 shares were sold at a weighted average price of $22.6735, leaving him with 132,913 common shares held directly.
He also received new awards: stock options for 70,000 shares at a $23.16 exercise price, 47,000 new RSUs, and 66,000 performance stock units. The options vest 25% after one year and the rest monthly over three years. The RSUs vest in four equal annual installments. The PSUs can deliver up to 66,000 shares based on cumulative total shareholder return goals over a three-year period ending January 12, 2029.
Zymeworks Inc. executive Hollywood Mark, EVP & Chief Operating Officer, filed an initial ownership report showing his equity stake in the company as of January 9, 2026. He directly owns 121,367 shares of common stock. In addition, he holds several stock options to buy common shares, including 80,000 options at $15.23 expiring in 2029 and other grants through 2035 at exercise prices ranging from $7 to $35.20. Mark also holds restricted stock units, with 20,000 RSUs from a January 2024 grant and 53,000 RSUs from a January 2025 grant, each RSU representing the right to receive one share of common stock upon vesting.
Zymeworks Inc. director Brian N. Cherry reported new equity awards granted on January 12, 2026. He received a stock option for 23,000 shares of common stock at an exercise price of $23.16 per share, vesting in 36 equal monthly installments starting one month after the grant date. He also received 15,400 restricted stock units (RSUs), each representing the right to receive one share of common stock upon vesting. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. Both awards are reported as directly owned following the transactions.
Zymeworks Inc. director Brian N. Cherry filed an initial ownership report stating that he does not beneficially own any of the company’s securities. As of January 12, 2026, the filing shows zero non-derivative shares of Zymeworks Inc. held and no derivative securities, such as options or warrants, beneficially owned. The filing is made as a Form 3, which discloses a director’s starting ownership position when they become subject to insider reporting rules.
Zymeworks Inc.'s EVP & Chief Medical Officer, Jeffrey T. L. Smith, reported the vesting of 17,666 restricted stock units (RSUs) on January 12, 2026, which converted into the same number of common shares at $0.00 per share. These RSUs were part of a grant made on January 10, 2025 that vests in three equal annual installments, with each RSU delivering one share of common stock upon vesting.
On the same date, 9,310 common shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and related fees under mandatory “sell to cover” provisions, and not as a discretionary sale. After these transactions, Smith beneficially owned 26,708 common shares and 35,334 RSUs, all reported as directly held.
Zymeworks Inc. director Gregory Austin Ciongoli reported new equity awards on a Form 4. On January 12, 2026, he was granted stock options covering 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036.
He also received 7,700 restricted stock units (RSUs) on the same date. Each RSU represents the right to receive one share of common stock upon vesting, and these RSUs vest on January 12, 2027. All reported derivative holdings are shown as directly owned, and the filing reflects awards being acquired rather than any sale of shares.
Zymeworks Inc. director Kelvin Neu reported new equity awards in a Form 4 dated January 12, 2026. He was granted 11,500 stock options with an exercise price of $23.16 per share and 7,700 restricted stock units (RSUs), all held as direct beneficial ownership.
The stock options and RSUs both vest on January 12, 2027. Each RSU gives the right, upon vesting, to receive one share of Zymeworks common stock. These transactions reflect equity compensation to a board member rather than open-market buying or selling.
Zymeworks Inc. reported that director Robert E. Landry received new equity awards. On January 12, 2026, he was granted stock options to buy 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036, leaving him with 11,500 derivative securities beneficially owned after the grant.
On the same date, he was also granted 7,700 restricted stock units (RSUs), each representing the contingent right to receive one share of common stock upon vesting. These RSUs vest on January 12, 2027, and 7,700 derivative securities are shown as beneficially owned directly following the transactions.
Zymeworks Inc. director Alessandra Cesano received new equity awards, including stock options and restricted stock units. On January 12, 2026, she was granted stock options covering 11,500 shares of common stock and 7,700 restricted stock units. The footnotes state that the options vest on January 12, 2027 and that each RSU converts into one share of common stock upon vesting, with the RSUs also vesting on January 12, 2027. These awards are reported as directly owned following the transactions.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
